AI4Eyes Graduates from Creative Destruction Lab AI & Wins RBCx Innovation Prize
AI4Eyes completed the CDL-Montreal AI cohort, with co-founders
Throughout the CDL program, AI4Eyes was challenged to sharpen its strategy, refine its vision, and focus on the goals that will create the greatest impact. For a healthcare technology company, that discipline is essential.
"CDL pushed us to think differently, focus on execution of growth critical matters in nine months program. The experience helped us set bold goals, strengthen our business strategy, and build momentum for what comes next." Dr.
As part of the program, AI4Eyes was also awarded the RBCx Innovation Prize, recognizing the company's progress, potential, and commitment to innovation in health technology.
AI4Eyes extends its sincere thanks to the CDL-Montreal AI mentors who contributed their guidance and expertise throughout the cohort, including
With this achievement, AI4Eyes will continue advancing its mission to bring innovative AI-powered tools to optometry/ophthalmology and improve the way eye care professionals detect, monitor, and manage dry eye disease.
To learn more about Creative Destruction Lab, visit: https://creativedestructionlab.com/
To learn more about AI4Eyes, visit: https://www.aiforeyes.com
View original content to download multimedia:https://www.prnewswire.com/news-releases/ai4eyes-graduates-from-creative-destruction-lab-ai--wins-rbcx-innovation-prize-302767349.html
SOURCE AI4Eyes Medical Technologies Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Westchester Medical Center Health Network Names Frances Spreer Albert, CPA, Executive Vice President and Chief Financial Officer
- Abbott and NACHC launch nationwide Food for Health initiative to make nutritious food a core part of healthcare
- Harvey Unleashes the BABY GYRO AIR G-200H: 550 Air Watts of Shop-Vacuum Fury -- With No Filter Bags Required
Create E-mail Alert Related Categories
PRNewswire, Press ReleasesSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share